Jacobs Designs and Builds Award-Winning Facility for Novartis
February 12 2013 - 7:45AM
Business Wire
Jacobs Engineering Group Inc. (NYSE:JEC) announced today that a
project it executed on behalf of Novartis received a 2013 Facility
of the Year Award (FOYA) from the International Society for
Pharmaceutical Engineering (ISPE), INTERPHEX and Pharmaceutical
Processing magazine, sponsors of the awards program.
The U.S. Flu Cell Culture Facility at the Novartis Campus in
Holly Springs, N.C. received the FOYA for Process Innovation. The
facility uses an innovative cell culture technology to manufacture
seasonal and pandemic influenza vaccines. Judges cited the creative
solution of containment convertibility that allows the facility to
run at lower levels to reduce operating costs during routine
seasonal influenza production, yet still maintain the capability of
operating at higher containment levels when required. Jacobs
provided design services, engineering, procurement and construction
management for the facility.
In making the announcement, Jacobs Group Vice President Bob
Pragada stated, “It was a privilege to work with Novartis on their
award-winning facility. We appreciate their continued trust in us,
and value our long-standing relationship.”
The FOYA program recognizes pharmaceutical manufacturing
projects that use new and innovative technologies to enhance
project delivery and reduce production costs of high quality
medicines for patients worldwide. Another Jacobs project was named
the overall winner of the 2012 award.
Jacobs is one of the world's largest and most diverse providers
of technical, professional, and construction services.
Statements made in this release that are not based on historical
fact are forward-looking statements. We base these forward-looking
statements on management’s current estimates and expectations as
well as currently available competitive, financial and economic
data. Forward-looking statements, however, are inherently
uncertain. There are a variety of factors that could cause business
results to differ materially from our forward-looking
statements. For a description of some of the factors which may
occur that could cause actual results to differ from our
forward-looking statements please refer to our 2012 Form 10-K, and
in particular the discussions contained under Items 1 - Business,
1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's
Discussion and Analysis of Financial Condition and Results of
Operations. We do not undertake to update any forward-looking
statements made herein.
Jacobs Engineering (NYSE:JEC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Jacobs Engineering (NYSE:JEC)
Historical Stock Chart
From Jul 2023 to Jul 2024